Sweden In-Vitro Diagnostics Market | Growth, Trends, and Forecast (2020-2025)

ABOUT THIS REPORT
- Market Snapshot
- Market Overview
- Scope of the Report
- Key Market Trends
- Competitive Landscape
- Major Players
TABLE OF CONTENTS

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

CAGR:

5.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Swedish in vitro diagnostics market is expected to witness a CAGR of 5.2% during the forecast period.

Certain factors that are driving the market growth include high prevalence of chronic diseases, increasing use of point-of-care (POC) diagnostics, advanced technologies, and increasing awareness and acceptance of personalized medicine and companion diagnostics.
Rising geriatric population is expected to be one of the major factor impacting growth of the market. According to Statistics Sweden’s population projection, in 2018, the share of people aged 80 and older will increase most to 19.86% of total population, and in 2028, their share is expected to be 255,000 more people than today, an increase of 50 percent.
Effective management of patients with one or more chronic disease is a commonly debated concern in Sweden. More effective primary care delivery may increase the overall efficiency and responsiveness of the health system. Hence, the increasing health expenditure in the country is expected to fuel the market growth over the forecast period.

Scope of the Report

As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as chronic diseases.

By Test Type
		Clinical Chemistry
		Molecular Diagnostics
		Immuno Diagnostics
		Haematology
		Other Types

Product
		Instrument
		Reagent
		Other Products

Usability
		Disposable IVD Devices
		Reusable IVD Devices

Application
		Infectious Disease
		Diabetes
		Cancer/Oncology
		Cardiology
		Autoimmune Disease
		Other Applications

End Users
		Diagnostic Laboratories
		Hospitals & Clinics
		Other End Users

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Reagent Segment is Expected to Hold the Highest Market Share During the Forecast Period

The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, or preparations intended by the manufacturer to be used during the in vitro diagnosis process. Given the high cost of many diagnostic platforms, it is common for manufacturers to lease equipment instead of selling technology outright to end users. In these arrangements, the lease is tied to contracts to purchase associated reagents or assays for the equipment over the term of the contract. Many diagnostic companies have in excess of 75% of sales from consumables, such as assays and reagents, and such agreements guarantee the generation of cyclic revenues associated with the sale of reagents and other consumables.

To understand key trends, Download Sample Report

Competitive Landscape

The Swedish in vitro diagnostics market is highly competitive and consists of a number of major players. Companies, like Abbott Laboratories, Becton, Dickinson, and Company, Bio-Rad Laboratories Inc., Danaher Corporation, Johnson & Johnson, Roche Diagnostics, Siemens Healthcare, and Thermo Fisher Scientific Inc., among others, hold the substantial market share in the Swedish in vitro diagnostics market.

Major Players

You can also purchase parts of this report. Do you want to check out a section wise price list?

1. INTRODUCTION
1. 1.1 Study Deliverables
2. 1.2 Study Assumptions
3. 1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
1. 4.1 Market Overview
2. 4.2 Market Drivers
  1. 4.2.1 High Prevalence of Chronic Diseases
  2. 4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
  3. 4.2.3 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
3. 4.3 Market Restraints
  1. 4.3.1 Stringent Regulations
  2. 4.3.2 Cumbersome Reimbursement Procedures
4. 4.4 Porter's Five Forces Analysis
  1. 4.4.1 Threat of New Entrants
  2. 4.4.2 Bargaining Power of Buyers/Consumers
  3. 4.4.3 Bargaining Power of Suppliers
  4. 4.4.4 Threat of Substitute Products
  5. 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
1. 5.1 By Test Type
  1. 5.1.1 Clinical Chemistry
  2. 5.1.2 Molecular Diagnostics
  3. 5.1.3 Immuno Diagnostics
  4. 5.1.4 Haematology
  5. 5.1.5 Other Types
2. 5.2 Product
  1. 5.2.1 Instrument
  2. 5.2.2 Reagent
  3. 5.2.3 Other Products
3. 5.3 Usability
  1. 5.3.1 Disposable IVD Devices
  2. 5.3.2 Reusable IVD Devices
4. 5.4 Application
  1. 5.4.1 Infectious Disease
  2. 5.4.2 Diabetes
  3. 5.4.3 Cancer/Oncology
  4. 5.4.4 Cardiology
  5. 5.4.5 Autoimmune Disease
  6. 5.4.6 Other Applications
5. 5.5 End Users
  1. 5.5.1 Diagnostic Laboratories
  2. 5.5.2 Hospitals & Clinics
  3. 5.5.3 Other End Users
6. COMPETITIVE LANDSCAPE
1. 6.1 Company Profiles
  1. 6.1.1 Abbott Laboratories
  2. 6.1.2 Becton, Dickinson, and Company
  3. 6.1.3 BioMerieux
  4. 6.1.4 Bio-Rad Laboratories Inc.
  5. 6.1.5 Danaher Corporation
  6. 6.1.6 QIAGEN
  7. 6.1.7 F. Hoffmann-La Roche AG
  8. 6.1.8 Siemens Healthcare
  9. 6.1.9 Thermo Fisher Scientific Inc.

*List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

** Subject to Availability

**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments